Haoxi Health Terminates $80 Million At-The-Market Equity Offering

summarizeSummary

Haoxi Health Technology Ltd. has mutually agreed with Aegis Capital Corp to terminate its previously announced $80 million at-the-market equity program, with no shares having been sold under the agreement.

check_boxKey Events

• ATM Program Termination

  Haoxi Health Technology Ltd. and Aegis Capital Corp mutually terminated the at-the-market equity program established on January 23, 2026.

• No Shares Sold

  The company confirmed that no Class A Ordinary Shares were sold under the $80 million ATM sales agreement prior to its termination.

• Removes Dilution Overhang

  The termination eliminates the potential for significant future equity dilution that the large ATM program represented, which was previously a major concern given its size relative to the company's market capitalization.

auto_awesomeAnalysis

The termination of the $80 million at-the-market (ATM) equity program is a highly positive development for Haoxi Health Technology Ltd. This ATM program, initiated on January 23, 2026, represented a potential dilution exceeding the company's current market capitalization. The fact that no shares were sold before termination removes a significant overhang on the stock, alleviating concerns about substantial future dilution and potential downward pressure on share price. This suggests the company may have found alternative financing or decided against immediate capital raising through equity, which is favorable for existing shareholders.